Evidence map›Paper›PMID 25908833›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2015

Small-Animal PET Imaging of Pancreatic Cancer Xenografts Using a 64Cu-Labeled Monoclonal Antibody, MAb159.

Hui Wang, Dan Li, Shuanglong Liu, Ren Liu, Hong Yuan, Valery Krasnoperov, Hong Shan, Peter S Conti, Parkash S Gill, Zibo Li

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Stress-induced translocation of the endoplasmic reticulum chaperone GRP78/BiP and its impact on human disease and therapy.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  4. Review
  5. Theranostic application ofEuropean journal of nuclear medicine and molecular imaging · 2022
    Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Translational molecular imaging in exocrine pancreatic cancer.European journal of nuclear medicine and molecular imaging · 2018
    Review
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Hui WangDepartment of Radiology and Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Dan LiDepartment of Radiology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China Molecular Imaging Center, Department of Radiology, University of Southern California, Los Angeles, California Guangdong Provincial Engineering Research Center of Molecular Imaging, Guangzhou, China ziboli@med.unc.edu shanhong@mail.sysu.edu.cn.
Shuanglong LiuMolecular Imaging Center, Department of Radiology, University of Southern California, Los Angeles, California.
Ren LiuDepartment of Pathology, University of Southern California, Los Angeles, California; and.
Hong YuanDepartment of Radiology and Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Valery KrasnoperovVasgene Therapeutics Inc., Los Angeles, California.
Hong ShanDepartment of Radiology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China Guangdong Provincial Engineering Research Center of Molecular Imaging, Guangzhou, China ziboli@med.unc.edu shanhong@mail.sysu.edu.cn.
Peter S ContiMolecular Imaging Center, Department of Radiology, University of Southern California, Los Angeles, California.
Parkash S GillDepartment of Pathology, University of Southern California, Los Angeles, California; and.
Zibo LiDepartment of Radiology and Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina Molecular Imaging Center, Department of Radiology, University of Southern California, Los Angeles, California ziboli@med.unc.edu shanhong@mail.sysu.edu.cn.
University of Southern California · USImaging Center · USThird Affiliated Hospital of Sun Yat-sen University · CNUniversity of North Carolina at Chapel Hill · USVasGene Therapeutics (United States) · US

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
Development of sEphB4-HSA as Novel Therapeutic in CancerR44CA168158 · NCI · VASGENE THERAPEUTICS, INC · PI KRASNOPEROV, VALERY G · 2013 to 2014
$1.4M
The Tetrazine Ligation for Efficient 18F Labeling and Pretargeted Imaging/Radiotherapy of CancerR01EB014354 · NIBIB · UNIV OF NORTH CAROLINA CHAPEL HILL · PI FOX, JOSEPH M, LI, ZIBO · 2013 to 2016
$1.4M
sEphB4-HSA A Pre-Clinical Candidate for OncologyR43CA168158 · NCI · VASGENE THERAPEUTICS, INC · PI KRASNOPEROV, VALERY G · 2012 to 2012
$150k
EphB4 Receptor Tyrosine Kinase RTK Targeted Humanized Monoclonal Antibody h131R43CA171538 · NCI · VASGENE THERAPEUTICS, INC · PI KRASNOPEROV, VALERY G · 2012 to 2012
$112k
NCI NIH HHS CA168158-01NCI NIH HHS CA171538-01NCI NIH HHS P30 CA016086NCI NIH HHS P30-CA016086-35-37NCI NIH HHS R43 CA168158NCI NIH HHS R43 CA171538NCI NIH HHS R44 CA168158NIBIB NIH HHS 1R01EB014354-01A1NIBIB NIH HHS R01 EB014354
6 · The paper itself

Abstract

unlabelledOverexpression of the GRP78 receptor on cell surfaces has been linked with tumor growth, metastasis, and resistance to therapy. We developed a (64)Cu-labeled probe for PET imaging of tumor GRP78 expression based on a novel anti-GRP78 monoclonal antibody, MAb159.

methodsMAb159 was conjugated with the (64)Cu-chelator DOTA through lysines on the antibody. DOTA-human IgG was also prepared as a control that did not bind to GRP78. The resulting PET probes were evaluated in BXPC3 pancreatic cancer xenografts in athymic nude mice.

resultsThe radiotracer was synthesized with a specific activity of 0.8 MBq/μg of antibody. In BXPC3 xenografts, (64)Cu-DOTA-MAb159 demonstrated prominent tumor accumulation (4.3 ± 1.2, 15.4 ± 2.6, and 18.3 ± 1.0 percentage injected dose per gram at 1, 17, and 48 after injection, respectively). In contrast, (64)Cu-DOTA-human IgG had low BXPC3 tumor accumulation (4.8 ± 0.5, 7.5 ± 0.7, and 4.6 ± 0.8 percentage injected dose per gram at 1, 17, and 48 h after injection, respectively).

conclusionWe demonstrated that GRP78 can serve as a valid target for pancreatic cancer imaging. The success of this approach will be valuable for evaluating disease course and therapeutic efficacy at the earliest stages of anti-GRP78 treatment. Moreover, these newly developed probes may have important applications in other types of cancer overexpressing GRP78.

Indexed as

Copper RadioisotopesPositron-Emission TomographyRadiopharmaceuticalsAnimalsAntibodies, Monoclonal, HumanizedCell Line, TumorEndoplasmic Reticulum Chaperone BiPFemaleHeat-Shock ProteinsHeterocyclic Compounds, 1-RingHumansImmunoglobulin GMiceMice, NudeMicroscopy, FluorescenceNeoplasm Transplantation1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidAntibodies, Monoclonal, HumanizedCopper RadioisotopesEndoplasmic Reticulum Chaperone BiPHeat-Shock ProteinsHeterocyclic Compounds, 1-RingHSPA5 protein, humanHspa5 protein, mouseImmunoglobulin GRadiopharmaceuticals64CuGRP78pancreatic cancerPET

Identifiers

PMID25908833
PMCPMC5448786
OpenAlexW2119810396

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.